Form 4: Director James Mulay Receives Equity Grant at CG Oncology

Director James Mulay was granted 9,354 stock options in CG Oncology, Inc. as part of a standard equity compensation arrangement.

Summary

• Director James Mulay received a grant of 9,354 stock options on June 4, 2026.
• The options have an exercise price of $56.09 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs in 1/12th monthly increments following the grant date, with a provision for full vesting upon the next annual stockholder meeting if it occurs before the first anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the granted options.
• The exercise price of $56.09 may be subject to market fluctuations relative to the future share price.

Future Outlook

The options vest monthly over one year, incentivizing the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The use of monthly vesting schedules is consistent with standard equity compensation practices for board members in mid-cap biotech firms.
• The 10-year expiration term is a standard industry benchmark for executive and director stock option plans.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on a monthly basis starting July 2026.
• Potential exercise of options by the director upon vesting and subject to market conditions.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Options, Director Compensation